SuperworthKairos Pharma, LTD. EPS KAPA
Diluted earnings per share by quarter and over the last twelve months, from 2023.
- Last 12 months, to Jun 30, 2026
- −$1.96
- Latest quarter, Q2 FY26
- −$0.42
- Fiscal year 2025
- −$2.10
Kairos Pharma, LTD.'s earnings per share was −$1.96 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.42.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.10 | n/a |
| FY2024 | −$1.54 | n/a |
| FY2023 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.42 | n/a | −$1.96 | |
| Q1 FY26 | −$0.56 | n/a | −$2.10 | |
| Q4 FY25 | −$0.49 | n/a | −$2.10 | |
| Q3 FY25 | −$0.49 | n/a | −$2.10 | |
| Q2 FY25 | −$0.56 | n/a | −$2.31 | |
| Q1 FY25 | −$0.56 | n/a | −$1.89 | |
| Q4 FY24 | −$0.49 | n/a | −$1.54 | |
| Q3 FY24 | −$0.70 | n/a | −$1.82 | |
| Q2 FY24 | −$0.14 | n/a | −$1.33 | |
| Q1 FY24 | −$0.21 | n/a | n/a | |
| Q4 FY23 | −$0.77 | n/a | n/a | |
| Q3 FY23 | −$0.21 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Kairos Pharma, LTD.'s size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KAPAKairos Pharma, LTD. | −$1.96 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| Peer median | $0.19 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Kairos Pharma, LTD.
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.